Phase I, Reference-controlled, Dose Escalating Study to Examine the Pharmacokinetics and Safety of AeroVanc Inhalation Powder.

Trial Profile

Phase I, Reference-controlled, Dose Escalating Study to Examine the Pharmacokinetics and Safety of AeroVanc Inhalation Powder.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2014

At a glance

  • Drugs Vancomycin (Primary) ; Vancomycin (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections; Methicillin-resistant Staphylococcus aureus infections
  • Focus Adverse reactions
  • Sponsors Savara Pharmaceuticals
  • Most Recent Events

    • 12 Jun 2012 Results were presented, according to a Savara Pharmaceuticals media release.
    • 15 May 2012 Actual patients number is 25 as reported by ClinicalTrials.gov.
    • 15 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top